drugset / Trial / NCT04406649
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
NaSingle-groupOpen-labelTreatment
Summary
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Timeline
- Start
- 2020-09-14
- Primary completion
- 2023-01-16
- Completion
- 2023-01-16
Publications
- Ailani J, Charleston L 4th, Strom S, Albrecht D, Cowan R. Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open-label ASCEND acute migraine study. Headache. 2026 Mar;66(3):688-696. doi: 10.1111/head.15086. Epub 2025 Nov 4.
- Tepper SJ, Albrecht D, Ailani J, Kirby L, Strom S, Rapoport AM. Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study. CNS Drugs. 2024 Dec;38(12):1017-1027. doi: 10.1007/s40263-024-01118-8. Epub 2024 Oct 7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dihydroergotamine | Small molecule | 5.2 mg | Intranasal |